DATE
Sarepta Pursues Efficiency Measures Amid $1 Billion Debt Due in 2027
Sarepta Therapeutics; debt 2027; efficiency measures; ELEVIDYS; cost savings; restructuring; financial results 2025; FDA; Duchenne muscular dystrophy; stock decline
Bayer Layoffs Top 12,000 with More Cuts Expected Amid Ongoing Restructuring
Bayer; layoffs; restructuring; cost-cutting; employee reductions; Bill Anderson; 2025; pharma industry
Alnylam Surpasses $50B Market Cap as Amvuttra Heart Disease Launch Impresses Wall Street
Alnylam Pharmaceuticals; market cap; Amvuttra; heart disease; ATTR-CM; stock surge; Q2 2025 earnings; revenue growth
AstraZeneca Beats Q2 Estimates on Strong Cancer Drug Sales
AstraZeneca; Q2 2025; cancer drug sales; oncology portfolio; Tagrisso; Imfinzi; Enhertu; financial results
Merck Announces $3 Billion Cost-Cutting and Restructuring Plan
Merck; cost cutting; restructuring; job cuts; real estate reduction; Keytruda; pharmaceutical industry; Q2 2025 financials
GSK Strengthens COPD Offering via $12 Billion Multi-Program Deal with China’s Hengrui Pharma
GSK; Hengrui Pharma; COPD; biobucks; PDE3/4 inhibitor; HRS-9821; Nucala; immunology; oncology; licensing deal
Abivax aces pair of phase 3 ulcerative colitis trials as end of cash runway looms
Abivax; Obefazimod; ulcerative colitis; Phase 3 trial; clinical remission; ABTECT-1; ABTECT-2; cash runway; induction trials; oral miR-124 enhancer; maintenance trial
J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025
Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease
Recent Developments in Building Measurable Patient Support Programs (2025)
patient support programs; measurable outcomes; collaborative healthcare; 2025 trends; Medicare reforms; cost efficiency; access to care
Biopharma Layoffs Continue to Surge in First Half of 2025
biopharma; layoffs; 2025; workforce reductions; industry trends; biotech closures; year-over-year increase